The hematopoietic stem cell transplantation in Hodgkin's disease: questions and controversies.
Most patients with Hodgkin's disease (HD) are cured with chemotherapy and/or radiotherapy. However, half of those with advanced stage disease (IIIB, IV) do not respond adequately to treatment or relapse. Salvage therapy used in such cases gives from 10% to 50% complete remission but only 10% long term survival. The results of bone marrow transplantation reported in acute leukemia and non-Hodgkin's lymphoma encouraged some authors to develop this new therapeutic strategy in Hodgkin's disease. In the early 1980's promising results were achieved when refractory and relapsed patients were selected to receive myeloablative therapy followed by bone marrow transplantation. Today, high dose chemotherapy with hematopoietic stem cell transplantation (HSCT) is used more and more often in poor prognosis Hodgkin's disease. After a review of the literature concerning the results of transplantation in Hodgkin's disease, we develop the numerous problems associated with this procedure which remain to be solved such as: the optimal indication, the timing of HSCT, the type of graft, the conditioning regimen, the place of radiotherapy and the optimal use of hematopoietic growth factors. We conclude with future prospects.
Fleury
J
J
Centre Jean Perrin, Unité de Transplantation Médullaire, Clermont-Ferrand, France.
Legros
M
M
Cure
H
H
Tortochaux
J
J
Condat
P
P
Dionet
C
C
Travade
P
P
Belembaogo
E
E
Tavernier
F
F
Kwiatkowski
F
F
D000367:Age Factors; D005544:Forecasting; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D013997:Time Factors
D016298:Hematopoietic Cell Growth Factors